PODD241220P360000
- 0.00
- 0.000.00%
Insulet Newsroom
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Insulet Shares Are Trading Higher Amid Strength in Diabetes-related Stocks Following Weight Loss Data From Novo Nordisk.
DexCom, Insulet, Tandem Benefit From Novo Nordisk CagriSema Data
Executive VP Of Insulet Sold 26% Of Their Shares
Insulet Corporation (NASDAQ:PODD) Delivered A Better ROE Than Its Industry
Unusual Options Activity: DVN, GOOGL and Others Attract Market Bets, DVN V/OI Ratio Reaches 78.9
EST Dec 16th Closing Delivery - In the last three hours of trading, 7 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Insulet Is Maintained at Overweight by JP Morgan
Nephron Research Adjusts Price Target on Insulet to $310 From $285
RMD or PODD: Which Is the Better Value Stock Right Now?
Insulet (NASDAQ:PODD) Might Have The Makings Of A Multi-Bagger
J.P. Morgan Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $330
Morgan Stanley Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $317
Insulet's Strong International Performance and Optimistic Type 2 Diabetes Market Outlook Drive Positive Analyst Rating
Decoding 11 Analyst Evaluations For Insulet
Citi's 'SMID Value Creators' Stocks: GAP, CHWY, FHN, and More
Wells Fargo Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $305
Citi Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $310
Jefferies Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $340
Insulet (PODD) Receives a Buy From Jefferies
Insulet To Present At Nasdaq 51st Investor Conference; Webcast At 5:30 AM ET